BAGSVAERD, Denmark and MOUNTAIN VIEW, Calif. – Novo Nordisk and Glooko have announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk’s deep knowledge of diabetes with Glooko’s digital platform and data analytics expertise.
“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” said Christian Kanstrup, senior vice president, Stategy, Access & Marketing, Novo Nordisk, in a statement. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”
Building on Glooko’s mobile and web platforms, the companies plan to deliver personalized, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. The partnership’s joint offerings will also assist health care professionals to engage and manage patients with the aid of population-wide data reporting. By integrating these offerings within its Digital Health Platform developed with IBM Watson Health, Novo Nordisk hopes to generate increasingly valuable insights into diabetes management and treatment outcomes.
Glooko is a population health platform for diabetes management which enables people with diabetes to track and better manage their condition using mobile, web and cloud technology. Glooko’s mobile app enables individuals to sync their data from diabetes and exercise devices including blood glucose meters. The company’s population health application enables care teams to remotely support people with diabetes and is focused on improving patient satisfaction and outcomes at a lower cost.
“Glooko’s partnership with Novo Nordisk aims to empower tens of millions of patients with digital tools to make diabetes management easier”, said Rick Altinger, Glooko CEO, in a statement. “We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world.”